These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8753690)

  • 1. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.
    Moretti JL; Azaloux H; Boisseron D; Kouyoumdjian JC; Vilcoq J
    Eur J Nucl Med; 1996 Aug; 23(8):980-6. PubMed ID: 8753690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.
    Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M
    Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.
    De Moerloose B; Van de Wiele C; Dhooge C; Philippé J; Speleman F; Benoit Y; Laureys G; Dierckx RA
    Eur J Nucl Med; 1999 Apr; 26(4):396-403. PubMed ID: 10199946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
    Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
    J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake and washout of 99mTcV-dimercaptosuccinic acid and 99mTc-sestamibi in the assessment of histological type and grade in breast cancer.
    Papantoniou V; Christodoulidou J; Papadaki E; Valotassiou V; Souvatzoglou M; Louvrou A; Feida H; Sotiropoulou M; Pampouras G; Michalas S; Zerva C
    Nucl Med Commun; 2002 May; 23(5):461-7. PubMed ID: 11973487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (99M)Technetium-sestamibi scintimammography in non-palpable breast lesions found on screening X-ray mammography.
    Gommans GM; van der Zant FM; van Dongen A; Boer RO; Teule GJ; de Waard JW
    Eur J Surg Oncol; 2007 Feb; 33(1):23-7. PubMed ID: 17126524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 99mTc-(V)DMSA scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI.
    Papantoniou V; Christodoulidou J; Papadaki E; Valotassiou V; Stipsanelli A; Louvrou A; Lazaris D; Sotiropoulou M; Pampouras G; Keramopoulos A; Michalas S; Zerva C
    Eur J Nucl Med; 2001 Jul; 28(7):923-8. PubMed ID: 11504092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [99mTc-MIBI characterization of breast microcalcifications. Correlations with scintigraphic and histopathologic findings].
    Vanoli C; Antronaco R; Giovanella L; Ceriani L; Sessa F; Fugazzola C
    Radiol Med; 1999; 98(1-2):19-25. PubMed ID: 10566292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography.
    Papantoniou V; Tsiouris S; Mainta E; Valotassiou V; Souvatzoglou M; Sotiropoulou M; Nakopoulou L; Lazaris D; Louvrou A; Melissinou M; Tzannetaki A; Pirmettis I; Koutsikos J; Zerva C
    Breast Cancer Res; 2005; 7(1):R33-45. PubMed ID: 15642168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response.
    Burak Z; Ersoy O; Moretti JL; Erinç R; Ozcan Z; Dirlik A; Sabah D; Basdemir G
    Eur J Nucl Med; 2001 Sep; 28(9):1341-50. PubMed ID: 11585293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantified 99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients: factors that influence the level of 99m Tc-MIBI uptake.
    Fuster D; Muñoz M; Pavia J; Palacín A; Bellet N; Mateos JJ; Martín F; Ortega M; Setoain FJ; Pons F
    Nucl Med Commun; 2002 Jan; 23(1):31-8. PubMed ID: 11748435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients.
    Takamura Y; Miyoshi Y; Taguchi T; Noguchi S
    Cancer; 2001 Jul; 92(2):232-9. PubMed ID: 11466674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
    Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
    J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up.
    Khalkhali I; Cutrone J; Mena I; Diggles L; Venegas R; Vargas H; Jackson B; Klein S
    J Nucl Med; 1995 Oct; 36(10):1784-9. PubMed ID: 7562043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings.
    Kao CH; Tsai SC; Liu TJ; Ho YJ; Wang JJ; Ho ST; ChangLai SP
    Cancer Res; 2001 Feb; 61(4):1412-4. PubMed ID: 11245443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
    Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
    J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
    Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
    J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
    Yokogami K; Kawano H; Moriyama T; Uehara H; Sameshima T; Oku T; Goya T; Wakisaka S; Nagamachi S; Jinnouchi S; Tamura S
    Eur J Nucl Med; 1998 Apr; 25(4):401-9. PubMed ID: 9553170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancer.
    Cwikla JB; Buscombe JR; Kolasinska AD; Parbhoo SP; Thakrar DS; Hilson AJ
    Anticancer Res; 1999; 19(3B):2299-304. PubMed ID: 10472348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
    Sergieva SB; Timcheva KV; Hadjiolov ND
    J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.